RMAT Designation: FDA Expedited Program Guide

The Regenerative Medicine Advanced Therapy (RMAT) designation is an expedited program established under Section 3033 of the 21st Century Cures Act and codified at Section 506(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act, 21 U.S.C. § 356(g)). Administered by the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), RMAT accelerates clinical development and review for regenerative therapies addressing serious conditions. As described on the official FDA program page on November 10, 2026, RMAT designation provides sponsors with Fast Track and Breakthrough Therapy benefits, including early FDA interactions and statutory flexibilities for accelerated approval.

What It Is and Who Runs It

The RMAT designation is administered by CBER, primarily through the Office of Therapeutic Products (OTP), which was elevated to a Super Office within CBER in 2023 succeeding the former Office of Tissues and Advanced Therapies (OTAT). Through RMAT, the FDA provides early multidisciplinary guidance on trial designs, surrogate endpoints, and biomanufacturing scale-up. Qualifying products must be regulated as biologics under Section 351 of the Public Health Service (PHS) Act; understanding what is a biologic drug is essential to confirming that a therapy falls within this regulatory scope.

Eligible regenerative therapies include:

Cell therapies: Autologous or allogeneic products, including stem-cell therapies using induced pluripotent stem cells, and CAR T-cell therapies.
Tissue engineering products: Scaffolds and cellular constructs designed to regenerate tissues, as covered in our guide to tissue engineering.
Human cell and tissue products: Cellular therapies not qualifying for minimal manipulation exemptions.
Combination products: Biologics combined with medical devices or delivery matrices.
Certain gene therapies: Therapies modifying cellular function, and xenogeneic cell products.

The statute explicitly excludes products regulated solely under Section 361 of the PHS Act (42 U.S.C. § 264) and 21 CFR Part 1271, which are minimally manipulated and intended solely for homologous use. RMAT applies strictly to therapies requiring an Investigational New Drug (IND) application and a Biologics License Application (BLA).

Eligibility

Under Section 506(g)(1) of the FD&C Act and FDA Guidance for Industry (February 2019), a therapeutic candidate is eligible for RMAT designation if it satisfies three statutory criteria:

Regenerative Medicine Therapy: The product meets the definition of a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or qualifying combination product (excluding Section 361 HCT/Ps).
Serious Condition: The therapy is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition.
Preliminary Clinical Evidence: Preliminary clinical evidence indicates that the therapy has the potential to address unmet medical needs for that condition.

Unlike FDA Fast Track designation, which can be granted based on preclinical models, RMAT strictly requires preliminary human clinical evidence; in vitro data alone cannot support an RMAT request. Furthermore, unlike Breakthrough Therapy designation, which requires showing substantial improvement over available treatments, RMAT requires showing the potential to address unmet medical needs without requiring comparative superiority at submission.

Acceptable clinical evidence may derive from prospective trials, single-arm open-label studies, historical controls, or well-designed retrospective case series, including foreign studies conducted under Good Clinical Practice (GCP).

What It Funds or Requires

RMAT designation is an administrative and regulatory status rather than a financial grant; it provides no direct funding or research subsidies. Instead, it provides regulatory mechanisms that compress development timelines.

Core regulatory benefits under Section 506(g) include:

Fast Track Features: Frequent meetings with CBER staff and Rolling Review of BLA modules before full application completion.
Breakthrough Therapy Features: Intensive guidance on efficient drug development beginning as early as Phase 1, involving senior CBER leadership.
Surrogate and Intermediate Endpoints: Section 506(g)(5) directs the FDA to hold early multidisciplinary meetings to agree upon surrogate or intermediate endpoints to support accelerated approval.
Accelerated Approval Flexibilities: RMAT biologics qualify for accelerated approval under Section 506(c) based on surrogate endpoints or data from a meaningful number of trial sites.
Flexible Post-Approval Pathways: Under Section 506(g)(7), confirmatory requirements can be satisfied through patient registries, electronic health records (RWE), larger confirmatory data sets, or monitoring of pre-approval patient cohorts.
Priority Review Eligibility: Designated products may receive Priority Review upon BLA submission, shortening the FDA review clock from 10 months to 6 months.

Application or Compliance Steps

Sponsors apply for RMAT designation through CBER across five administrative steps:

Maintain an Active IND: Submit concurrently with an initial IND or as an amendment to an active IND. CBER will not review requests if the IND is on clinical hold.
Compile the Dossier: Provide product characterization, proof of serious indication, unmet need analysis, and preliminary human clinical data.
Use Mandatory Cover Letter Text: CBER guidelines mandate exact bold uppercase notation on the cover letter:
- For an IND amendment: REQUEST FOR REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION
- With an initial IND: INITIAL INVESTIGATIONAL NEW DRUG SUBMISSION and REQUEST FOR REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION
Transmit via ESG: Submit in eCTD format through the FDA Electronic Submissions Gateway (ESG) to CBER Document Control.
Maintain Compliance: Engage in formal Type B meetings (pre-IND, End-of-Phase 2, and pre-BLA) and fulfill annual IND reporting obligations while maintaining product comparability across bioprocess changes.

Typical Timeline Phases

The RMAT pathway unfolds across operational phases rather than fixed calendar dates:

Phase 1: Pre-Submission Clinical Data: The sponsor conducts early investigations under an active IND or foreign equivalent, often in a pilot cohort or Phase 2 clinical trial, generating preliminary human evidence.
Phase 2: Statutory 60-Day Review: Under Section 506(g)(4), the FDA must review the request and notify the sponsor in writing within 60 calendar days of receipt.
Phase 3: Expedited Development: The sponsor participates in Type B meetings with CBER OTP leadership to establish surrogate endpoints and comparability protocols.
Phase 4: Rolling BLA Review: The sponsor submits completed BLA sections under rolling review, targeting a 6-month review if granted Priority Review.
Phase 5: Post-Marketing Confirmation: Following accelerated approval, the sponsor conducts agreed-upon real-world evidence studies or registries to verify long-term efficacy.

Common Mistakes

Applicants frequently encounter denials or delays due to recurring procedural errors:

Submitting Without Human Data: Relying solely on animal or in vitro data; RMAT strictly mandates preliminary human clinical evidence.
Submitting Under Clinical Hold: Requesting designation while an IND is under clinical hold; CBER will not process requests until hold issues are resolved.
Misclassifying Section 361 Products: Submitting minimally manipulated tissues that do not require Section 351 biologics licensing.
Arguing Superiority Over Unmet Need: Focusing on comparative superiority rather than demonstrating how the therapy addresses an unmet need.
Product Comparability Deficits: Generating clinical data with an early formulation that differs substantially from the commercial product.
Omitting Cover Letter Labels: Failing to include the mandatory bold uppercase designation text on the formal cover letter.

Related Programs

The table below summarizes how RMAT compares to related FDA expedited programs:

Program	Statutory Basis	Scope	Qualifying Evidentiary Bar	Submission Timing	FDA Review Clock
RMAT Designation	FD&C Act § 506(g)	Regenerative biologics (CBER)	Preliminary clinical evidence of potential to address unmet need	With IND or amendment; ideally before EOP2	60 calendar days
Fast Track Designation	FD&C Act § 506(a)	Drugs and biologics	Nonclinical or clinical data showing potential to address unmet need	With IND or amendment; prior to BLA/NDA	60 calendar days
Breakthrough Therapy	FD&C Act § 506(a)	Drugs and biologics	Preliminary clinical evidence of substantial improvement over care	With IND or amendment; ideally before EOP2	60 calendar days
Priority Review	FD&C Act § 506(c)	Drugs and biologics	Significant improvement in safety or effectiveness	Submitted with original BLA or NDA	6 months
Accelerated Approval	FD&C Act § 506(c)	Drugs and biologics	Surrogate endpoint reasonably likely to predict clinical benefit	Discussed during development; filed with BLA	Standard or Priority review clock

Frequently Asked Questions

What is the difference between RMAT designation and Breakthrough Therapy designation?

Breakthrough Therapy applies across all drug classes and requires clinical evidence showing substantial improvement over available treatments. RMAT applies specifically to regenerative medicine biologics and requires clinical evidence showing the potential to address unmet medical needs, without mandating comparative superiority. Furthermore, Section 506(g)(7) authorizes post-approval real-world evidence and registry models for accelerated approval confirmation.

Can international clinical trial data support an RMAT request?

Yes. The FDA accepts data from foreign clinical trials conducted under Good Clinical Practice (GCP), provided the investigational product is analytically comparable to the product intended for U.S. clinical trials.

Does RMAT designation guarantee Accelerated Approval or Priority Review?

No. RMAT designation facilitates early discussions regarding surrogate endpoints and priority review eligibility, but does not guarantee approval. Sponsors must demonstrate that clinical data satisfy statutory standards upon BLA submission.

Can an RMAT designation be rescinded?

Yes. If subsequent development fails to support initial findings, or if an approved therapy eliminates the unmet need, CBER may rescind the designation.

What happens if an RMAT request is denied?

A denial does not affect active IND status. CBER issues a written rationale explaining why criteria were not met, allowing sponsors to reapply with additional data.

Sources

U.S. FDA CBER: Regenerative Medicine Advanced Therapy Designation. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation (Accessed: November 10, 2026).
U.S. FDA CBER: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions (February 2019). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-regenerative-medicine-therapies-serious-conditions (Accessed: November 10, 2026).
United States Code: 21 U.S.C. § 356(g) — Regenerative advanced therapies. https://www.law.cornell.edu/uscode/text/21/356 (Accessed: November 10, 2026).
Code of Federal Regulations: Title 21, Part 1271 — Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) (Accessed: November 10, 2026).